All News

GCA,woman

In Giant Cell Arteritis, Hospital Admission Is Bad News

d MedPage Today

One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.

Read Article
OP_0.jpg

ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis

d EurekAlert!

The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults.

Read Article
young.doctors.business.talent

2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology

d ACR

The American College of Rheumatology is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology.

Read Article
sit,sedentary,couch,coffee,comfort

Extreme Global Costs of Physical Inactivity

d Jack Cush, MD

A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for non-communicable diseases (NCDs) and mental health conditions, it also imparts a considerable health and economic burden that is avoidable.

Read Article
2002-2019 Canadian study of Rheumatology care: access has improved but problems exist, esp w/ DMARD use. In 112,494 new RA pts, 84% saw Rheum <1yrs w/ 43% increase by 2019. Suboptimal DMARD use in elderly improved 55 to 69% https://t.co/tpv514P0GP https://t.co/AIRuf7u60d

Links:

Dr. John Cush RheumNow ( View Tweet)
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/D0eQWcON2J https://t.co/rK77lCmbVv https://t.co/5X0e6DBxAh https://t.co/ZpJtc8SdcG

Links:

Dr. John Cush RheumNow ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/22DhyJUeuo

Links:

Dr. John Cush RheumNow ( View Tweet)

Welcome, January 2023 ❄️. It's the 50th year of the publication @jrheum ✨🎊! View the full issue online 👉 https://t.co/GsZdjMZF1T #rheumatoidarthritis #spondyloarthritis #psoriaticarthritis #lupus #vasculitis #pediatric #gout #rheumatology #50thyearofpublication #jrheum50 https://t.co/keUVRVD8vW

Links:

The Journal of Rheumatology jrheum ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/D2GYjbR7y2 #BestOf2022

Links:

Dr. John Cush RheumNow ( View Tweet)

INBUILD Study of 170 pts with autoimmune related ILD showed nintedanib signifi. slowed the rate of FVC decline in FVC decline over 52 wks (NIN -75.9 mL/yr vs PBO -178.6 mL/yr). AE's (mostly diarrhea) leading to D/C was NIN 17.1% vs PBO 10.2% https://t.co/CmbF5NQMfJ #BestOf2022

Links:

Dr. John Cush RheumNow ( View Tweet)

608 EARLY RA pts in BARFOT study had Xrays over time. 24% did not show Erosions after 8 yrs. Pt w/ NO Erosions were younger, younger, w Less ACR criteria, & seronegative at Dx. They had more TJC, less SJC, lower ESR, less DMARDs & pred Rx. https://t.co/5jYNd7bwE3 https://t.co/z3Y0TPJTwd

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGISTS: have you ever ordered a Fibroscan in patients taking Methotrexate?

Dr. John Cush RheumNow ( View Tweet)

Nifty little read about dx and tx algorithms in monogenic autoinflammatory disease I think we need to start generating more diagnostic algorithms and "approach to" articles Working on a series for my fellows and have had a hard time finding material! https://t.co/DYmgSyjILi
Mike Putman EBRheum ( View Tweet)
There is considerable overlap between fibromyalgia tender points and an enthesitis score in axial spondyloarthritis pts. 526 pts in the Predict-SpA study (53% men, 38% FM) assessed 18 TP and 13 Entheses found ICC between both scores of 0.7 https://t.co/ESmP26plDB https://t.co/7X1XhyML0f

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2022: Allopurinol Safety in CKD Patients https://t.co/BDjuL2Fp94 https://t.co/d3Jo4SKwHQ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDG-PET Scan in RA? Study of 34 #RA pts shows PET uptake (SUV scores) measures were significantly correlated with the number of swollen joints, SDAID but not the CDAI, disease duration, seropositivity, or RA treatments. https://t.co/AkGhEiNqwt https://t.co/FkKh49KYyd

Links:

Dr. John Cush RheumNow ( View Tweet)
10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement. https://t.co/BeYOq8ysgW https://t.co/pLogz1HHTV

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-18 is a proinflammatory cytokine involved in innate & adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity https://t.co/1SXlODZcXc https://t.co/xtauaMMMos

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Use Lead to Melanoma? A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible. https://t.co/dChsIsCAMt https://t.co/5PgjlunTmp

Links:

Dr. John Cush RheumNow ( View Tweet)
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/jPNIuaYdnJ https://t.co/efZG5kG2Yd

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×